This is what they had to say by way of explanation: A recent study found glucagon like peptide-1 receptor agonist (GLP-1 RA) treatment in the US has risen more than 700 percent over the past four years
In the TRANSCEND-T2D-1 trial (published in The Lancet , June 2026), individuals with type 2 diabetes lost -15.3% at 12 mg over 40 weeks
Patients should immediately contact their healthcare provider if they experience serious side effects such as seizures, severe mood changes, hypersensitivity reactions, or signs of mania or psychosis
The peptide modulates nitric oxide synthesis, which governs vascular tone, blood flow, and inflammatory responses across gut, muscle, and neural tissue
Mediators Inflamm (2013) 2013:750540